SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Papa John's International, Inc. engages in the operation and franchise of pizza delivery and carryout restaurants. It operates through the following segments: Domestic Company-owned Restaurants, North America Franchising, North America Commissaries, International Operations, and All Others. The Domestic Company-Owned Restaurants segment consists of retail sales of pizza and side items, breadsticks, cheese sticks, chicken poppers and wings, dessert items, and canned and bottled beverages. The North America Franchising segment involves the offering of sales and support activities, development rights, and collection of royalties from franchisees located in the United States and Canada. The North America Commissaries segment includes the eleven full-service regional dough production and distribution and quality control centers. The International Operations segment represents all restaurant operations outside of the United States and Canada. The All Others segment focuses on franchise contributions to marketing funds and sale, company-owned and franchised restaurants, information systems and related services used in restaurant operations, point-of-sale system, online and other technology-based ordering platforms, printing, and promotional items. The company was founded by John H. Schnatter in 1984 and is headquartered in Louisville, KY.

Papa John`s International, Inc.

Take-private speculation is the dominant topic, centered on Irth Capitals reported bid and a major U.S. franchisee joining the effort; traders are debating whether a deal will materialize, with no confirmed agreement in the discussion. The takeover hopes contrast with criticism of management and concern over weak sales, a dividend suspension, and the stocks steep decline.

TOSHI

A burst of trading volume and a recent rebound have fueled talk of a technical breakout and a possible short squeeze in TOSHI, with many holders buying dips and anticipating a move through resistance. Others point to repeated failed breakouts, weak price action, and broader crypto-market softness; talk of an upcoming announcement or listing remains speculative.

Onyx is an infrastructure for a multi-asset, scalable, and cryptographically secure ledger. Onyx functions as a blockchain-based technology that enhances financial ecosystems by enabling a more efficient and interconnected economy, with a mission to develop cryptographic ledgers that optimize security, scalability, and usability. XCN is native to the Onyx XCN Ledger Blockchain as well as the Onyx Goliath Blockchain. XCN is also used as an ERC-20 token for Staking and Governance.

Onyxcoin

A sharp, news-unconfirmed XCN spike is driving attention, with traders reacting to a large candle and debating whether it marks a rebound or another brief pump-and-dump. Some are buying the dip and pointing to Bitcoins bounce, while skeptics say XCNs past spikes have quickly faded.

Amgen, Inc. is a biotechnology company, which engages in the discovery, development, manufacture, and marketing of human therapeutics. The company was founded by William K. Bowes, Jr., Franklin Pitcher Johnson, Jr., George B. Rathmann, and Joseph Rubinfeld on April 8, 1980 and is headquartered in Thousand Oaks, CA.

AMGEN Inc.

Amgens Phase 3 lung cancer results for IMDELLTRA plus AstraZenecas IMFINZI, which reduced the risk of death in first-line extensive-stage small cell lung cancer, are driving attention. Traders see the findings as a potential growth catalyst and debate how much they could expand the drugs commercial role alongside established products such as Repatha.

ProShares Trust II - ProShares Ultra Bloomberg Crude Oil 2x Shares

ProShares Ultra Bloomberg Crude Oil

Crudes rally amid escalating Middle East tensions and fears of disrupted oil supplies is driving attention to UCO. Traders are divided between following the bullish momentum and positioning for a pullback, with some noting that geopolitical headlines could quickly shift the oil trade.

Select Sector SPDR Trust (The) - State Street Energy Select Sector SPDR ETF

Energy Select Sector SPDR Fund

XLE is drawing attention after reaching a new high as energy stocks outperform, with traders pointing to rising crude prices and supply risks tied to Middle East tensions and shipping disruptions. The conversation is broadly bullish on the breakout, though some traders warn the rally may be extended and question whether it can hold.

Merck & Co., Inc. is a health care company, which engages in the provision of health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products. It operates through the following segments: Pharmaceutical, Animal Health, and Other. The Pharmaceutical segment includes human health pharmaceutical and vaccine products. The Animal Health segment discovers, develops, manufactures, and markets animal health products, such as pharmaceutical and vaccine products, for the prevention, treatment and control of disease in livestock, and companion animal species. The Other segment consists of sales for the non-reportable segments of healthcare services. The company was founded in 1891 and is headquartered in Rahway, NJ.

Merck & Co Inc

Mercks attention centers on Phase 3 results for its partnership with Moderna: the personalized cancer vaccine added to Keytruda reduced melanoma recurrence or death risk, drawing interest in the oncology platform and potential commercial upside. Traders debate whether the results justify further gains, given high expectations, unapproved status, and questions about manufacturing complexity and expansion beyond melanoma.

Celcuity, Inc. operates as a cellular analysis company. The company discovers new cancer sub-types and commercializing diagnostic tests designed to improve the clinical outcomes of cancer patients treated with targeted therapies. The firm's proprietary CELx diagnostic platform is the commercially ready technology that uses a patient's living tumor cells to identify the specific abnormal cellular process driving a patient's cancer and the targeted therapy that treats it. The company was founded by Brian F. Sullivan and Lance G. Laing in January 2012 and is headquartered in Minneapolis, MN.

Celcuity Inc

Updated Phase 3 VIKTORIA-1 breast-cancer subgroup data presented at ESMO is drawing attention, with traders highlighting stronger progression-free survival and response results for gedatolisib combinations. Reactions are mixed: some see the findings as compelling, while others note the data builds on previously released topline results and say CELC still needs to demonstrate commercial uptake and revenue.

Shiba Inu (SHIB) is a decentralized, community-led cryptocurrency ecosystem built on the Ethereum blockchain. Originally launched as a meme-based project, it has evolved into a comprehensive financial ecosystem designed to offer a decentralized alternative to traditional banking. Its main value proposition lies in its transition from a social phenomenon into a functional utility network, supported by a vast global community known as the ShibArmy and a commitment to 100% community ownership with no central leadership.  The ecosystem features its own decentralized exchange, ShibaSwap, where users can trade, provide liquidity, and earn rewards. To address Ethereum’s high costs and slow speeds, the project utilizes Shibarium, a Layer 2 scaling solution that processes transactions faster and more affordably.  The project employs a unique three-token model to manage its economy and governance. SHIB serves as the primary currency for trading and payments, while LEASH offers scarcity-based incentives for dedicated supporters. BONE acts as the governance token, allowing holders to vote on proposals through the Doggy DAO and serving as the native gas token for the Shibarium network.

Shiba Inu

SHIB is drawing attention for choppy, largely sideways trading, with repeated technical posts describing consolidation and traders watching for a breakout. Holders are split between accumulating and anticipating a rebound, while skeptics point to weak momentum, limited utility, and the risk of further declines.

Anthropic

Anthropics anticipated blockbuster IPO is driving attention, with traders weighing rapid revenue growth against heavy compute commitments and reported losses. Some see a major AI-growth opportunity, while skeptics question whether the spending and intensifying competition can support the expected valuation.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Leadership Shifts Toward Quality Stocks? Sector ETFs to Play

Market leadership may be shifting from momentum to quality. These sector ETFs offer exposure to resilient earnings and attractive valuations.

INMD Stock Draws Investor Attention On Q4 Financial Update

Equity

The company said it anticipated its fourth-quarter (Q4) sales to fall within a tight range of $103.6 million to $103.8 million, compared with the analyst consensus estimate of $104.64 million, according to FiscalAI data. 


UBS says this sector remains a high-quality, defensive investment theme

Investing.com -- UBS continues to view the medical devices sector as a high-quality, defensive investment theme, supported by long-term demographic shifts and rising global demand.

Citi shuffles MedTech stocks: BDX downgraded, ITGR raised; reiterates top pick

Investing.com -- Citi analysts revised their MedTech coverage following a volatile first quarter, with several rating changes and adjustments to target prices.

HSBC shuffles MedTech stocks, cutting 4, upgrading 2

Investing.com -- HSBC has reshuffled its ratings across the MedTech and Life Sciences sector, upgrading   Siemens  Healthineers AG  (ETR:SHLG) and Sonova (SIX:SOON) to Buy while cutting  Align Technology  (NASDAQ:ALGN), Eurofins Scientific SE (EPA:EUFI), IQVIA, and Smith&Nephew (LON:SN) to Hold.

Are Wall Street Analysts Predicting Cooper Companies Stock Will Climb or Sink?

Cooper Companies has underperformed the broader market over the past year, but analysts are highly optimistic about the stock’s prospects.

DexCom Crashed 40% In A Single Day Last Week; Gains 19% More Stocktwits Watchers

The firm revised down its full-year sales guidance which led to a slew of analyst downgrades. Retail investors are betting on the $750 million share repurchase program announced by the firm to buoy shares.

SPDR Series Trust - State Street SPDR S&P Health Care Equipment ETF

Neutral Sentiment

<ul class="summary-bullets"><li>The firm is scheduled to report its financial performance for Q4 and fiscal 2025 ahead of the market open on Tuesday, Feb. 10, 2026.</li><li>The company’s total revenue for fiscal 2025 is projected around $370.2 million to $370.4 million.</li><li>Looking ahead, the company has set a revenue forecast for fiscal 2026 between $365 million and $375 million.</li></ul><p>InMode (INMD) stock is gaining investor attention in Friday’s premarket after the medical technology provider announced its fourth quarter (Q4) sales outlook.</p><p>The company said it anticipated its fourth-quarter (Q4) sales to fall within a tight range of $103.6 million to $103.8 million, compared with the analyst consensus estimate of $104.64 million, according to FiscalAI data.&nbsp;</p><h2 class="st-heading-2">2025 And 2026 Outlook&nbsp;</h2><p>The firm is scheduled to report its financial performance for Q4 and fiscal 2025 ahead of the market open on Tuesday, Feb. 10, 2026. The company’s total revenue for fiscal 2025 is projected to be around $370.2 million to $370.4 million, below the analysts' consensus estimate of $371 million, as per FiscalAI data.</p><p>InMode expects a non-GAAP gross margin near the high end of the 70% range for the full 2025 fiscal year.&nbsp;Looking ahead, the company has set a revenue forecast for fiscal 2026 between approximately $365 million and $375 million.&nbsp;<a href="https://stocktwits.com/symbol/INMD">InMode stock</a> inched 0.8% higher in Friday’s premarket.&nbsp;</p><h2 class="st-heading-2">What Are Stocktwits Users Saying?&nbsp;</h2><p>On Stocktwits, retail sentiment around the stock remained in ‘bullish’ territory while message volume shifted to ‘high’ from ‘normal’ levels in 24 hours.&nbsp;</p><figure class="image"><img src="https://news.stocktwits-cdn.com/Screenshot_2026_01_09_055125_png_79a97af5f3.webp" alt="INMD’s Sentiment Meter and Message Volume as of 05:45 a.m. ET on Jan. 9, 2026 | Source: Stocktwits" width="926" height="105"></figure><p>A bullish Stocktwits user highlighted sequential growth and high margins.&nbsp;</p><p><stembedurl>https://stocktwits.com/thinkandpick/message/641307067</stembedurl></p><p>Another user pointed to ongoing pressure in the aesthetic device sector, noting that demand remains subdued, but added that the latest outlook broadly aligns with the company’s earlier outlook for 2025, suggesting performance is tracking as expected.</p><p><stembedurl>https://stocktwits.com/findingthestock/message/641285697</stembedurl></p><h2 class="st-heading-2">Brokerage Radar&nbsp;</h2><p>In December, Canaccord cut its price target on InMode to $15 from $16 and kept a ‘Hold’ rating on the stock, according to TheFly. The firm said it still has a positive long-term view on the medical technology industry going into 2026, noting that mid-sized company valuations remain low, and deal activity is increasing.</p><p>INMD stock has declined by over 10% in the last 12 months.&nbsp;</p><p>Also See:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/trump-big-oil-invest-at-least-100-billion-venezuela/cmU29w3R4d2">Trump Says Big Oil Will Invest At Least $100 Billion To Rebuild Venezuela's Oil Infrastructure</a></p><p><i>For updates and corrections, email newsroom[at]stocktwits[dot]com.</i></p>

 A worker produces medical instrument at Shandong Yixing Medical Instrument Co., Ltd.

The company said it anticipated its fourth-quarter (Q4) sales to fall within a tight range of $103.6 million to $103.8 million, compared with the analyst consensus estimate of $104.64 million, according to FiscalAI data. 

iShares US Medical Devices ETF

Inmode Ltd

First Trust Exchange-Traded Fund VI - First Trust Indxx Medical Devices ETF

SPDR S&P Health Care Equipment ETF

Up more than 1%

Flat to up 1%

Flat to down 1%

Down more than 1%

What do you think the S&amp;P 500&#39;s ($SPY) return will be next week?

Feed

News

Sentiment

Fundamentals

Info

XHE SPDR S&P Health Care Equipment ETF

Fundamentals

Latest XHE News